資源描述：
《冠狀病毒Coronavirusl論文-1992 Intestinal protection against challenge with transmissible gastroenteritis virus of pigs immune after infection wit.pdf》由會員上傳分享，免費在線閱讀，更多相關內(nèi)容在學術論文-天天文庫。
1、ConferenceAbstractsdisease(usingthemethodofRiepenhoff-Taltyetal.,J.Med.serotype1,2or4infections,norbetweenmonotypes1AandVirol.1981,8,212-222)in47childrenaged6-24months,1C,norbetweenelectropherotypes.Thesameserotypecausedadmittedwithserotype1illness,15wi
2、thserotype2and46withsimilardiseaseseverityindifferentyears.Itislogicaltoaimserotype4.Serotype1strainsweresubdividedintomonotypesforstimulationofimmunityagainstallcommonserotypesin1Aand1C.Monotype1Cstrainswereelectropherotyped.Therearotavirusvaccine.were
3、nostatisticallysignificantdifferencesinsymptomsbetweenIntestinalprotectionagainstchallengewithtransmissiblegastroenteritisvirusofpigsimmuneafterinfectionwiththeporcinerespiratorycoronavirusE.Cox,M.B.PensaertandP.CallebautLaboratoryofVeterinaryVirologyan
4、dImmunology,Casinoplein24,B-9000Gent,BelgiumIn1984,aporcinerespiratorycoronavirus(PRCV)has4weekslater.TGEV-replicationand/or-excretioncouldnotemerged,whichisantigenicallycloselyrelatedtothebedemonstratedforlongerthan2and4daysafterPRCVenteropathogenictra
5、nsmissiblegastroenteritisvirus(TGEV).inoculationbyaerosolandintragastrical,respectively.PRCVreplicatesinepithelialcellsintherespiratorytractandNon-immunepigsexcretedTGEVover6days.Thenotinenterocytesinpigsof5weeksoldorolder.AninfectionTGEV-challengeinduc
6、edrapidlya4-to139-foldriseinwithPRCVinducesantibodieswhichneutraliseTGEVandvirusneutralisingantibodytitersinmostPRCV-immunepigs.PRCVtothesametiter.ItwasdeterminedifPRCV-immuneExperimentsareinprogresstoelucidatethemechanismbypigsshowedanintestinalprotect
7、ionagainstTGEV.Therefore,whichaPRCV-infectioninducesapartialintestinalimmunity6-week-oldseronegativepigswereinoculatedbyaerosoloragainstaTGEV-infectionandtoexamineifthisimmunityalsointragastricallywithPRCVandwerechallengedwithTGEVisinducedinthepresenceo
8、fmaternalPRCV-antibodies.Studiesonimmuneresponsesandinterferenceoforalpoliovaccine(OPV)onseroconversiontorotavirusvaccineS.Migasena,S.Simasathien,R.Samakoses,P.Pitisuttitham,C.AreeandB.PrayurahongVaccineTrialCentre,MahidolUnivers
